Head to Head Comparison: Belite Bio (NASDAQ:BLTE) versus Tenaya Therapeutics (NASDAQ:TNYA)

Tenaya Therapeutics (NASDAQ:TNYA) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Tenaya Therapeutics and Belite Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1	0	5	1	2.86
Belite Bio	1	1	6	0	2.63

Tenaya Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 487.37%. Belite Bio has a consensus target price of $202.33, suggesting a potential upside of 20.98%. Given Tenaya Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than Belite Bio.

Valuation and Earnings

This table compares Tenaya Therapeutics and Belite Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60 million	($0.62)	-1.10
Belite Bio	N/A	N/A	-$77.61 million	($2.30)	-72.72

Belite Bio is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tenaya Therapeutics and Belite Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-85.20%	-69.96%
Belite Bio	N/A	-19.49%	-19.05%

Volatility & Risk

Tenaya Therapeutics has a beta of 2.98, suggesting that its stock price is 198% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.22, suggesting that its stock price is 222% less volatile than the S&P 500.

Institutional and Insider Ownership

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 48.7% of Tenaya Therapeutics shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Tenaya Therapeutics beats Belite Bio on 8 of the 12 factors compared between the two stocks.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.